Raise Follow-on offering: $155.3M (total, as published), announced Oct 27, 2025. Source: company release on GlobeNewswire. source ↗
Raise Private placement: $85M (total, as published), announced Aug 13, 2025. Source: company release on GlobeNewswire. source ↗
Raise Private placement: $60M (total, as published), announced Aug 12, 2025. Source: SEC filing. source ↗
Trial start Phase 1: A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic source ↗
Partnership Partnership / licensing: €28.5M (upfront, as published); deal value up to €226M (kept separate from upfront), announced Jan 13, 2025. Source: SEC filing. source ↗
Trial start Phase 3: A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections source ↗
Trial start Phase 1/Phase 2: A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders source ↗
Trial start Phase 1: A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 source ↗
Trial start Phase 3: Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome source ↗
Trial start —: A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome source ↗
Trial start Phase 1/Phase 2: Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma source ↗
Trial start Phase 2: A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome source ↗
Trial start Phase 1: X4P-001 and Pembrolizumab in Patients With Advanced Melanoma source ↗
Trial start Phase 1/Phase 2: Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma source ↗
Trial start Phase 1: A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers source ↗
Upcoming milestones
2027-09 (ESTIMATED) · Phase 3 · A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections · NCT06056297
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $300.3M. Last 2 years.
Follow-on offering: $155.3M (total, as published), announced Oct 27, 2025. Source: company release on GlobeNewswire. source ↗
Private placement: $85M (total, as published), announced Aug 13, 2025. Source: company release on GlobeNewswire. source ↗
Private placement: $60M (total, as published), announced Aug 12, 2025. Source: SEC filing. source ↗
Partnership / licensing: €28.5M (upfront, as published); deal value up to €226M (kept separate from upfront), announced Jan 13, 2025. Source: SEC filing. source ↗
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
